310 related articles for article (PubMed ID: 24316309)
1. Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix.
Wu CH; Ko JL; Chen SC; Lin YW; Han CP; Yang TY; Chien MH; Wang PH
Gynecol Oncol; 2014 Feb; 132(2):474-82. PubMed ID: 24316309
[TBL] [Abstract][Full Text] [Related]
2. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.
Ding G; Fang J; Tong S; Qu L; Jiang H; Ding Q; Liu J
Prostate; 2015 Jun; 75(9):957-68. PubMed ID: 25728945
[TBL] [Abstract][Full Text] [Related]
3. Implication of human nonmetastatic clone 23 Type 1 and its downstream gene lipocalin 2 in metastasis and patient's survival of cancer of uterine cervix.
Wang PH; Ko JL; Yang SF; Lin LY
Int J Cancer; 2011 Nov; 129(10):2380-9. PubMed ID: 21442621
[TBL] [Abstract][Full Text] [Related]
4. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
5. Lipocalin2 enhances the matrix metalloproteinase-9 activity and invasion of extravillous trophoblasts under hypoxia.
Kobara H; Miyamoto T; Suzuki A; Asaka R; Yamada Y; Ishikawa K; Kikuchi N; Ohira S; Shiozawa T
Placenta; 2013 Nov; 34(11):1036-43. PubMed ID: 23972287
[TBL] [Abstract][Full Text] [Related]
6. Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells.
Tian Y; Zhao L; Wang Y; Zhang H; Xu D; Zhao X; Li Y; Li J
Asian J Androl; 2016; 18(4):607-12. PubMed ID: 26698234
[TBL] [Abstract][Full Text] [Related]
7. Lipocalin 2 promotes the migration and invasion of esophageal squamous cell carcinoma cells through a novel positive feedback loop.
Du ZP; Wu BL; Xie YM; Zhang YL; Liao LD; Zhou F; Xie JJ; Zeng FM; Xu XE; Fang WK; Li EM; Xu LY
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2240-50. PubMed ID: 26190820
[TBL] [Abstract][Full Text] [Related]
8. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
[TBL] [Abstract][Full Text] [Related]
9. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
Jamieson SM; Gu Y; Manesh DM; El-Hoss J; Jing D; Mackenzie KL; Guise CP; Foehrenbacher A; Pullen SM; Benito J; Smaill JB; Patterson AV; Mulaw MA; Konopleva M; Bohlander SK; Lock RB; Wilson WR
Biochem Pharmacol; 2014 Mar; 88(1):36-45. PubMed ID: 24434189
[TBL] [Abstract][Full Text] [Related]
10. Increased adipose tissue expression of lipocalin-2 in obesity is related to inflammation and matrix metalloproteinase-2 and metalloproteinase-9 activities in humans.
Catalán V; Gómez-Ambrosi J; Rodríguez A; Ramírez B; Silva C; Rotellar F; Gil MJ; Cienfuegos JA; Salvador J; Frühbeck G
J Mol Med (Berl); 2009 Aug; 87(8):803-13. PubMed ID: 19466389
[TBL] [Abstract][Full Text] [Related]
11. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
[TBL] [Abstract][Full Text] [Related]
12. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer.
Byrns MC; Duan L; Lee SH; Blair IA; Penning TM
J Steroid Biochem Mol Biol; 2010 Feb; 118(3):177-87. PubMed ID: 20036328
[TBL] [Abstract][Full Text] [Related]
13. HIC1 silencing in triple-negative breast cancer drives progression through misregulation of LCN2.
Cheng G; Sun X; Wang J; Xiao G; Wang X; Fan X; Zu L; Hao M; Qu Q; Mao Y; Xue Y; Wang J
Cancer Res; 2014 Feb; 74(3):862-72. PubMed ID: 24295734
[TBL] [Abstract][Full Text] [Related]
14. Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.
Dozmorov MG; Azzarello JT; Wren JD; Fung KM; Yang Q; Davis JS; Hurst RE; Culkin DJ; Penning TM; Lin HK
BMC Cancer; 2010 Dec; 10():672. PubMed ID: 21134280
[TBL] [Abstract][Full Text] [Related]
15. Lipocalin 2 expression is associated with aggressive features of endometrial cancer.
Mannelqvist M; Stefansson IM; Wik E; Kusonmano K; Raeder MB; Øyan AM; Kalland KH; Moses MA; Salvesen HB; Akslen LA
BMC Cancer; 2012 May; 12():169. PubMed ID: 22559235
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of lipocalin-2 suppresses the growth and invasion of prostate cancer cells.
Tung MC; Hsieh SC; Yang SF; Cheng CW; Tsai RT; Wang SC; Huang MH; Hsieh YH
Prostate; 2013 Sep; 73(12):1281-90. PubMed ID: 23775308
[TBL] [Abstract][Full Text] [Related]
17. Aldo-keto reductase 1C3 may be a new radioresistance marker in non-small-cell lung cancer.
Xie L; Yu J; Guo W; Wei L; Liu Y; Wang X; Song X
Cancer Gene Ther; 2013 Apr; 20(4):260-6. PubMed ID: 23519145
[TBL] [Abstract][Full Text] [Related]
18. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
Adeniji AO; Twenter BM; Byrns MC; Jin Y; Chen M; Winkler JD; Penning TM
J Med Chem; 2012 Mar; 55(5):2311-23. PubMed ID: 22263837
[TBL] [Abstract][Full Text] [Related]
19. AKR1C3 overexpression mediates methotrexate resistance in choriocarcinoma cells.
Zhao J; Xiang Y; Xiao C; Guo P; Wang D; Liu Y; Shen Y
Int J Med Sci; 2014; 11(11):1089-97. PubMed ID: 25170291
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic induction of epithelial to mesenchymal transition by LCN2 mediates metastasis and tumorigenesis, which is abrogated by NF-κB inhibitor BRM270 in a xenograft model of lung adenocarcinoma.
Mongre RK; Sodhi SS; Sharma N; Ghosh M; Kim JH; Kim N; Park YH; Shin YG; Kim SJ; Jiao ZJ; Huynh do L; Jeong DK
Int J Oncol; 2016 Jan; 48(1):84-98. PubMed ID: 26573874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
